Pune, India, Aug. 10, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, global Antipsychotic Drugs Market Size was valued at USD 15.47 billion in 2022 and is projected to grow from USD 16.14 billion in 2023 to USD 24.35 billion by 2030, exhibiting a CAGR of 6.0% during the forecast period.
Psychiatric illness includes mental diseases symptoms of psychosis such as schizophrenia, bipolar disorder, and depression. Growing demand for the medications for these is attributed to the increased prevalence of schizophrenia and bipolar disorder.
This information is provided by Fortune Business Insights™ in its research report titled Antipsychotic Drugs Market, 2023-2030.
Key Industry Development-
- February 2023: Lupin launched a generic antipsychotic medication which is equivalent to Sunovion Pharmaceuticals Inc's Latuda tablets. It comes in strengths of 20, 40, 60, 80 and 120 mg in the U.S.
Request a Free Sample PDF – https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antipsychotic-drugs-market-101390
Key Takeaways –
- Antipsychotic Drugs Market size in North America was USD 8.05 billion in 2022
- Increased Prevalence of Mental Health Disorders to Surge Market Growth
- Strong Adoption of Long-Acting Injectables (LAIs) to Determine Market Growth Trajectory
- The schizophrenia segment is expected to hold a major market share during the projected period.
Discover the Leading Players Featured in the Report-
- H. Lundbeck A/S (Denmark)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson) (Belgium)
- Eli Lilly and Company (U.S.)
- ALLERGAN (AbbVie, Inc.) (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Dr. Reddy’s Laboratories Ltd. (India)
- Sumitomo Dainippon Pharma Co., Ltd. (Japan)
- Alkermes plc (Ireland)
- Bristol-Myers Squibb Company (U.S.)
Report Scope & Segmentation:
| Report Coverage | Details |
| Forecast Period | 2023 to 2030 |
| Forecast Period 2023 to 2030 CAGR | 6.0% |
| 2030 Value Projection | USD 24.35 Billion |
| Base Year | 2022 |
| Antipsychotic Drugs Market Size in 2022 | USD 15.47 Billion |
| Historical Data for | 2019 to 2021 |
| No. of Pages | 195 |
| Segments covered | Therapy Type, Drug Type and Geography |
Browse Complete Report Details- https://www.fortunebusinessinsights.com/industry-reports/antipsychotic-drugs-market-101390
Drivers & Restraints:
Increasing Cases Of Mental Disorders To Drive Market Growth
Increasing cases of mental disorders is anticipated to drive the antipsychotic drugs market growth. Increase in the number of patient pools globally is anticipated to drive the growth of the market. In 2022, according to World Health Organization (WHO), mental disorders are expected to cost the global economy an estimated USD 6.0 trillion by 2030. Rise in the number of R&D initiatives for the development of antipsychotic drugs.
However, strong benefits of the usage of these key market products for the treatment of a wide range of psychiatric illnesses is expected to hamper the market growth for antipsychotic drugs.
Segmentation:
By Disease
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
By Drug
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Brexpiprazole
- Paliperidone Palmitate
- Others
By Therapeutic Class
- First Generation
- Second Generation
- Third Generation
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Regional Insights:
North America Held The Largest Share Due To Increasing Cases Of Psychiatric Illnesses
North America is expected to lead the antipsychotic drugs market share due to increasing cases of psychiatric illnesses. The market was valued at USD 8.05 billion in 2022 with the strong prevalence of psychiatric illnesses in the region and the market presence of prominent biopharmaceutical companies.
Europe market held the second-largest regional market in the 2022 due to increased awareness and spending by government bodies regarding psychiatric illnesses.
Quick Buy - Antipsychotic Drugs Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101390
Competitive Landscape:
Robust Psychiatric Drug Portfolio By The Key Players To Drive Market Development
The market is dominated with various biopharmaceutical companies due to their robust psychiatric drug portfolio. Key market players are Janssen Global Services LLC and Otsuka Pharmaceutical Co. Ltd. The market is dominated with Janssen Global Services LLC. Another key company with a significant global market revenue share is Otsuka Pharmaceutical Co. Ltd. with strong antipsychotic drugs portfolio.
FAQs
How big is the Antipsychotic Drugs Market?
Antipsychotic Drugs Market size was USD 15.47 billion in 2022. It is expected to reach USD 24.35 billion in 2030.
How fast is the Antipsychotic Drugs Market growing?
The Antipsychotic Drugs Market will exhibit a CAGR of 6.0% during the forecast period, 2023-2030.
Related Reports:
Schizophrenia Drugs Market Size, Share, Revenue Forecast and Opportunities
Antidepressants Market Overview, Industry Share and Forecast
Central Nervous System Treatment Market Size, Share, Opportunities & Analysis
Anxiety Disorders and Depression Treatment Market Analysis, Global Size and Industry Share Forecast
Autism Spectrum Disorder Treatment Market Size, Share, Opportunities and Forecast
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
